Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

SWG Education Activities

Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).

Read more

EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias

Dates: September 21-22, 2018
Location: Warsaw, Poland
Chairs: T Robak,  G Gaidano, I Hus

Following successful previous editions, EHA is coordinating the third two-day tutorial in close collaboration with the Polish Society of Hematology and Transfusion Medicine on “Myeloid and Lymphoid Leukemias”.…

Read more

World Cancer Day 2013

World Cancer Day 2013 - Global Press Release

1.

Read more

SWG Educational Activities

MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget

Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).

Read more